Q3 EPS Estimate for Perspective Therapeutics Lifted by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for Perspective Therapeutics in a research note issued on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings of ($0.25) per share for the quarter, up from their prior estimate of ($0.32). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.07) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($0.99) EPS and Q4 2027 earnings at ($0.32) EPS.

Several other brokerages also recently issued reports on CATX. Piper Sandler reduced their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.38.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN:CATX opened at $3.10 on Friday. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16. The business’s 50 day simple moving average is $3.08 and its 200-day simple moving average is $3.94.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 44.22%.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after acquiring an additional 405,612 shares in the last quarter. Walleye Capital LLC grew its position in shares of Perspective Therapeutics by 375.8% in the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock worth $645,000 after acquiring an additional 148,013 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after acquiring an additional 60,019 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after acquiring an additional 25,697 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Trending Headlines about Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Brookline raised its 2026 EPS forecasts: The firm now expects a loss of $0.25 per share in Q3 2026, $0.26 in Q4 2026 and $0.99 for full-year 2026, compared with previous estimates of $0.32, $0.36 and $1.23, respectively. Smaller projected losses are a positive earnings revision and may support CATX shares.
• Positive Sentiment: Q4 2027 loss forecast issued: Brookline expects Perspective Therapeutics to report a $0.32-per-share loss in Q4 2027, providing investors with updated longer-term estimates.
• Neutral Sentiment: 2027 estimates remain loss-making: Brookline forecasts losses of $0.26 per share in Q1 2027, $0.27 in Q2, $0.30 in Q3 and $1.14 for full-year 2027. These forecasts suggest continued operating losses and do not indicate near-term profitability.
• Negative Sentiment: Piper Sandler lowered its expectations for the stock price: The price-target or valuation change signals a less favorable view of Perspective Therapeutics and could weigh on investor sentiment. Piper Sandler Has Lowered Expectations for Perspective Therapeutics Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.